Pilot Therapeutics
This article was originally published in The Tan Sheet
Executive Summary
Company retains Quintiles (Research Triangle Park, N.C.) to conduct a randomized, double-blind, placebo-controlled clinical study of Pilot's dietary supplement for asthmatics beginning in the fourth quarter. Resulting data will include information from a rising-dose tolerance study. Winston-Salem, N.C.-based Pilot plans to market the product as inhibiting the production of leukotrienes, which are asthma biomarkers. The supplement contains gammalinolenic acid and a delta-5 desaturase inhibitor (1"The Tan Sheet" July 10, p. 8)
You may also be interested in...
Pilot Therapeutics Asthma Supplement Eyes First Quarter 2001 Launch
Pilot Therapeutics' first dietary supplement - specifically designed for asthmatics - will not bear the disease name on labeling. Instead, the product will be marketed as inhibiting the production of leukotrienes, which are asthma biomarkers, Pilot said.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands